Kenvue Inc. (NYSE:KVUE) Receives $23.75 Consensus Target Price from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have been given a consensus rating of “Hold” by the thirteen analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $23.75.

KVUE has been the topic of several analyst reports. Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Finally, Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th.

Kenvue Trading Down 1.6 %

Shares of KVUE stock opened at $22.81 on Monday. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The firm’s fifty day simple moving average is $21.84 and its 200 day simple moving average is $22.39. The firm has a market capitalization of $43.59 billion, a P/E ratio of 43.03, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.60%. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Lansforsakringar Fondforvaltning AB publ acquired a new position in Kenvue during the 4th quarter valued at about $13,101,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Kenvue during the 4th quarter valued at about $26,982,000. Brooklyn FI LLC acquired a new position in Kenvue during the 4th quarter valued at about $948,000. Azzad Asset Management Inc. ADV lifted its position in Kenvue by 3.0% during the 4th quarter. Azzad Asset Management Inc. ADV now owns 291,915 shares of the company’s stock valued at $6,232,000 after purchasing an additional 8,532 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $316,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.